<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852630</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS- SBP-01</org_study_id>
    <nct_id>NCT01852630</nct_id>
  </id_info>
  <brief_title>Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure</brief_title>
  <official_title>A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of Liver&#xD;
           &amp; Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous Bacterial&#xD;
           Peritonitis) by ascitic fluid examination at admission.&#xD;
&#xD;
        2. SBP (Spontaneous Bacterial Peritonitis) will be diagnosed in the presence of absolute&#xD;
           neutrophil count (ANC &gt;250/mm3) with/without positive ascitic fluid culture and Patients&#xD;
           with SBP (Spontaneous Bacterial Peritonitis) included in the study will be randomized to&#xD;
           receive cefepime or imipenem.&#xD;
&#xD;
        3. However, other SBP (Spontaneous Bacterial Peritonitis) patients not included for&#xD;
           randomization will be given empirical therapy with 3rd generation cephalosporin&#xD;
           (ceftriaxone).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline evaluation:&#xD;
&#xD;
      Baseline clinical, laboratory and disease severity parameters will be evaluated for each&#xD;
      study patient.&#xD;
&#xD;
        1. Etiology of cirrhosis.&#xD;
&#xD;
        2. Severity of liver disease. CTP (Child-Turcotte-Pugh) score MELD (Model for End-stage&#xD;
           Liver Disease) score MELD (Model for End-stage Liver Disease)-Na score IMSAA score&#xD;
&#xD;
        3. Decompensations/complications of CLD (Chronic Liver Disease) UGI bleed, Hepatic&#xD;
           encephalopathy, AKI (Acute Kidney Injury) etc.&#xD;
&#xD;
        4. Laboratory investigations:&#xD;
&#xD;
      Serum electrolytes Liver function tests Kidney function tests Pro calcitonin USG/CT abdomen&#xD;
      Complete blood counts Coagulation parameters Ascitic fluid analysis- TLC, DLC, Protein,&#xD;
      sugar, culture, SAAG. Chest X ray PA view HBsAg and Anti-HCV and other etiological workup as&#xD;
      available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the Response to treatment in each intervention group. Response is defined as 25% reduction in ANC (Absolute Neutrophil Count) from baseline.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 days,1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>cefepime + Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefepime 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime + Albumin</intervention_name>
    <description>cefepime + Albumin will be given for 2 days</description>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem + Albumin</intervention_name>
    <description>Imipenem + Albumin will be given for 2 days.</description>
    <arm_group_label>cefepime + Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Cirrhotic Patients with SBP (Spontaneous Bacterial Peritonitis) having any of the&#xD;
        following risk factors would be considered as 'Difficult to Treat SBP' and would be&#xD;
        included -&#xD;
&#xD;
          1. Nosocomial SBP: occurence of SBP (Spontaneous Bacterial Peritonitis) after 48 hours of&#xD;
             hospital admission, or&#xD;
&#xD;
          2. Prior ascitic fluid infection with 3rd generation cephalosporin resistant organism, or&#xD;
&#xD;
          3. No response to treatment with 3rd generation cephalosporins after 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18 years.&#xD;
&#xD;
          2. Cirrhotics with SBP (Spontaneous Bacterial Peritonitis) managed as outpatients.&#xD;
&#xD;
          3. Post liver transplant, HIV patients.&#xD;
&#xD;
          4. Patients on systemic chemotherapy, immunosuppressant drugs.&#xD;
&#xD;
          5. Growth of bacteria resistant to intervention drugs in ascitic fluid culture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ankur Jindal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences (ILBS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

